{
    "clinical_study": {
        "@rank": "94262", 
        "arm_group": [
            {
                "arm_group_label": "Afatinib (BIBW2992)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomised, double-blind phase III trial will be performed in patients with head and\n      neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the\n      efficacy and safety of afatinib (BIBW 2992) with placebo as adjuvant therapy to patients who\n      have received definitive chemo-radiotherapy."
        }, 
        "brief_title": "LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy", 
        "completion_date": {
            "#text": "August 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma, Squamous Cell", 
                "Neoplasms, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically confirmed loco-regionally advanced head and neck\n             squamous cell carcinoma (HNSCC), stage III to IVb\n\n          -  Unresected tumour prior to chemo-radiotherapy (CRT)\n\n          -  Concomitant CRT completed prior to randomisation\n\n          -  After concomitant platinum-based CRT, no evidence of disease (NED) on clinical and\n             radiographic examinations\n\n          -  Eastern cooperative oncology group (ECOG) performance status 0 or 1\n\n        Exclusion criteria:\n\n          -  Patients with smoking history of less than or equal to 10 pack years and with primary\n             tumour site of base of tongue and/or tonsil\n\n          -  Cancer of nasopharynx, sinuses, and/or salivary glands\n\n          -  Prior treatment with epidermal growth factor receptor (EGFR)-targeted small\n             molecules, EGFR-targeted antibodies, and/or any investigational agents for HNSCC\n\n          -  Known pre-existing Interstitial Lung Disease (ILD)\n\n          -  Any past or present history of areca/betel-nut chewing or its derivatives for a\n             cumulative duration of more than 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131155", 
            "org_study_id": "1200.162"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Afatinib (BIBW2992)", 
                "description": "Once daily", 
                "intervention_name": "Afatinib", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86021 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86011 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86019 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86017 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86013 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kunming", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86016 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanchang", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanning", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86014 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86020 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86018 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "1200.162.86004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Keelung City", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.162.88603 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.162.88602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.162.88601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "China: China Food and Drug Administration (CFDA)", 
                "Singapore: Health Sciences Authority", 
                "South Korea: Ministry of Food and Drug Safety (MFDS)", 
                "Taiwan : Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease Free Survival (DFS)", 
            "safety_issue": "No", 
            "time_frame": "up to 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131155"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease Free Survival (DFS) rate at 2 years", 
                "safety_issue": "No", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "Health Related Quality of Life (HRQOL)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 years"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}